Zoe Walmsley

Zoe Walmsley

Auto-generated profile, based on publicly available information

Zoe Walmsley

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Journal of Psychopharmacology
Verified
Journal Article
Open access
RMR Hamish McAllister-Williams
R Hamish McAllister-Williams
NGNicola Goudie
Nicola Goudie
LALumbini Azim
Lumbini Azim
VBVictoria Bartle
Victoria Bartle
MBMichael Berger
Michael Berger
SWStuart Watson
Stuart Watson
Background: Options for ‘treatment-resistant bipolar depression’ (TRBD) are limited. Two small, short-term, trials of pramipexole suggest it might be an option. Aims: To evaluate the clinical effectiveness and safety of pramipexole in the management of TRBD. Methods: A multi-centre randomised, double-blind controlled trial including participants ⩾18 years old with TRBD (failure to respond, tolerate or clinical contraindication/patient refusal of ⩾2 of quetiapine, olanzapine, lamotrigine or lurasidone) randomised 1:1 to pramipexole (max 2.5 mg/day salt weight) or placebo added to ongoing mood stabiliser ( n = 39). Primary outcome: Quick Inventory of Depressive Symptoms, Self-rated (QIDS-SR) at 12 weeks. Up to 48 weeks follow-up. Results: Pramipexole ( n = 18) was associated with a greater reduction in QIDS-SR score at 12 weeks versus placebo ( n = 21, 4.4 (4.8) vs 2.1 (5.1)): a medium sized ( d = −0.72) but not statistically significant difference (95% CI: −0.4 to 6.3, p = 0.087). Similarly, there was a non-significant approximate 2-point ( d = −0.76) improvement in pleasure at 6 weeks (95% CI: −0.11 to 4.20). Significant advantages of pramipexole on QIDS-SR score (6.28 points: 95% CI: 1.85–10.71) and psychosocial function (5.36 points: 95% CI: 0.38–10.35) were seen at 36 weeks post-randomisation, and on the response (46% vs 6%; p = 0.026) and remission (31% vs 0%; p = 0.030) rates at trial exit (48 weeks or last available data after 16 weeks for those affected by the early study closure). Hypomania ratings were significantly higher at 12 weeks. Otherwise, pramipexole was well tolerated. Conclusions: Clinically large, but statistically non-significant, effects of pramipexole on depression at 12 weeks, with significant longer-term benefits on mood and function were observed. Pramipexole use was complicated by dose titration and increased hypomanic symptoms. The small sample size limits interpretation. Furthermore, larger randomised placebo-controlled trials are warranted.

1 May 2025 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
HMHamish McAllister-Williams
Hamish McAllister-Williams
NGNicola Goudie
Nicola Goudie
LALumbini Azim
Lumbini Azim
VBVictoria Bartle
Victoria Bartle
MBMichael Berger
Michael Berger
SWStuart Watson
Stuart Watson
Background: There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients. Objectives: Primary: to evaluate the clinical effectiveness of pramipexole versus placebo alongside routine mood-stabilising medications over 12 weeks in patients with treatment-resistant bipolar depression. Secondary: evaluate the impact of pramipexole on mood and anxiety, psychosocial function, cost-effectiveness, and safety and tolerability over 48 weeks. Design: Multicentre, randomised, placebo-controlled trial of pramipexole versus placebo in addition to standard-of-care mood stabilisers. Clinicians, researchers and participants were blinded throughout the duration of the study. Pre-randomisation stage (to adjust antipsychotics or commence mood stabilisers where required) before randomisation. Weekly online assessments of mood and anxiety from randomisation to week 52, with psychosocial function, quality of life and healthcare resource utilisation assessments conducted at regular intervals. Setting: Twenty-one National Health Service trusts and Health Boards across England and Scotland. Participants: Patients aged 18 years and over with a diagnosis of treatment-resistant bipolar depression currently under secondary care mental health services. Aim to randomise 290 participants. Interventions: Pramipexole or matched placebo orally once daily, titrated from 0.25 mg to maximum of 2.5 mg (salt weight) depending on efficacy and tolerability. Main outcome measures: Depression – Quick Inventory for Depressive Symptomology; anxiety – Generalised Anxiety Disorder-7-item scale; psychosocial functioning – Work and Social Adjustment Scale; hypomania/mania – Altman Self-rating Scale of Mania; tolerability – Treatment Satisfaction Questionnaire for Medication; well-being and quality of life – EuroQol-5 Dimensions, five-level version, ICEpop CAPability measure for Adults and Oxford CAPabilities questionnaire-Mental Health tools. Results: Thirty-nine participants randomised (18 to pramipexole and 21 to placebo) with 36 providing data for the primary analysis. Pramipexole led to greater reductions in depressive symptoms at 12 weeks compared to placebo [4.4 (4.8) vs. 2.1 (5.1)]: a medium-sized (d = −0.72) but not statistically significant difference (95% confidence interval −0.4 to 6.3; p = 0.087). There were some statistically significant positive effects of pramipexole on secondary outcomes (reduction in depressive symptoms at 36 weeks, response and remission rates at trial exit, psychosocial function). Pramipexole was associated with an increased rate of hypomania/manic symptoms, but this appeared to be reduced by coadministration with an antipsychotic. General tolerability of pramipexole was good. There were significant annual gains in health-related quality of life and capability-well-being and tendency towards reduced health and social care costs. Limitations: Small sample size and variable follow-up period due to recruitment during COVID-19 pandemic and the trial closing early. Participants limited to those in secondary care mental health services. All assessments only available in English. Conclusions: No change in clinical practice can be recommended as there was not a significant difference between pramipexole and placebo on the primary efficacy outcome measure. However, there was evidence of positive effects of pramipexole on mood, psychosocial function and quality of life. Future work: Replication in a larger population and research to investigate the impact of coadministration of antipsychotics alongside pramipexole. Trial registration: This trial is registered as ISRCTN72151939 and EudraCT 2018-2869-18. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/154/01) and is published in full in Health Technology Assessment; Vol. 29, No. 21. See the NIHR Funding and Awards website for further award information.

1 October 2025 in BMC Medicine
Verified
Journal Article
Open access
PDF file
HMHelen Mossop
Helen Mossop
ZWZoë Walmsley
Zoë Walmsley
NWNina Wilson
Nina Wilson
OAOpeyemi Agbeleye
Opeyemi Agbeleye
MBMichelle Bardgett
Michelle Bardgett
JWJames M. S. Wason
James M. S. Wason
Background: Adaptive designs are increasingly being used in clinical trials within diverse clinical areas. They can offer advantages over traditional non-adaptive approaches, including improved efficiency and patient benefit. The level of improvement observed in practice depends to a large degree on conducting interim analyses (at which adaptations can be made to the trial based on collected data) rapidly and to a high standard. Methods: The ROBust INterims for adaptive designs (ROBIN) project aimed to identify best practice for conducting high-quality and rapid interim analyses. This was done through evidence synthesis of published work, qualitative research with trial stakeholders working at public sector clinical trials units, engagement with patients and the public, and a meeting of trial stakeholders to discuss findings and agree recommendations. Results: This paper provides recommendations for teams that conduct adaptive trials about how to ensure interim analyses are done rapidly and to a high standard. We break down recommendations by stage of the trial. We also identify a lack of methodology on how best to involve patients in adaptive trials and related decision-making. A limitation of our recommendations is that the research was mostly focused on UK academic settings, although we believe much of the recommendations are relevant in other countries and to industry-sponsored trials. Conclusions: When following the recommendations outlined in this paper, the process of planning and executing interim analyses will be smoother; in turn, this will lead to more benefits from using adaptive designs.

1 November 2025 in Health Technology Assessment
Verified
Journal Article
Open access
EAEnoch F Akowuah
Enoch F Akowuah
RMRebecca H Maier
Rebecca H Maier
HHHelen C Hancock
Helen C Hancock
JWJanelle Wagnild
Janelle Wagnild
LVLuke Vale
Luke Vale
JZJoseph Zacharias
Joseph Zacharias
Background: The safety, effectiveness and cost-effectiveness of mitral valve repair via thoracoscopically guided minithoracotomy compared with conventional median sternotomy (Sternotomy) in patients with degenerative mitral valve regurgitation is uncertain and widely debated. Objectives: To determine if Mini was more effective than Sternotomy in terms of physical functioning and associated return to usual activities and was cost-effective compared with Sternotomy. Design: A pragmatic, multicentre, expertise-based, superiority, randomised trial. Participants: Adults with degenerative mitral valve regurgitation undergoing mitral valve repair surgery. Setting: Ten tertiary care institutions in the United Kingdom. Intervention: Mini or Sternotomy mitral valve repair performed by an expert surgeon. Blinding: Primary outcome measure [Short Form 36-item Health Survey, version 2 (SF-36v2) physical functioning score] was measured by an independent assessor, blinded to allocation. Echocardiographic findings were measured in a core laboratory, blinded to allocation. Outcome Measures: Primary outcomes were physical functioning and associated return to usual activities measured by change from baseline in SF-36v2 physical function domain at 12 weeks following index surgery. The primary economic measure was incremental cost per quality-adjusted life-year over the year following surgery. Secondary outcomes included recurrent mitral regurgitation grade, physical activity and quality of life measured at time points to 1 year. Safety outcomes included death, repeat mitral valve surgery or heart failure hospitalisation up to 1 year. Results: Between November 2016 and January 2021, 330 participants were randomised; 166 to Mini and 164 to Sternotomy. Of these, 309 underwent surgery and 294 reported the primary outcome. Thirty per cent were female. At 12 weeks, mean difference between groups in the change in SF-36v2 physical function T -scores was 0.68 (95% confidence interval −1.89 to 3.26). Valve repair rates (96%) were similar in both groups. Echocardiography demonstrated mitral regurgitation severity as none or mild for 92% of participants at 1 year in both groups. The composite safety outcome occurred in 5.4% (9/166) of Mini and 6.1% (10/163) of Sternotomy participants at 1 year. On average, Mini was more costly £29,424 (95% confidence interval 26,909 to 31,940) versus £27,397 (95% confidence interval 25,172 to 29,620) and more effective 0.81 quality-adjusted life-years (95% confidence interval 0.78 to 0.84) versus 0.78 (95% confidence interval 0.75 to 0.81) than Sternotomy. The adjusted incremental cost-effectiveness ratio was £74,863 per quality-adjusted life-year for the comparison between Mini and Sternotomy. Mini has a probability of < 50% of being cost-effective at the range of willingness-to-pay values considered. Limitations: To minimise bias, SF-36v2 and all echocardiographic measures were independently assessed by personnel blinded to allocation. Expertise-based randomisation was important to address the limitations of previous studies; however, it is possible that it may have introduced potential confounders. Conclusions: Mini is not superior to Sternotomy in recovery of physical function at 12 weeks. Mini achieves high rates and quality of valve repair and has similar safety outcomes at 1 year to Sternotomy. The balance of probabilities favoured Sternotomy as the preferred surgical procedure in the base-case analysis over the range of willingness-to-pay values society might consider worthwhile for a quality-adjusted life-year. Nevertheless, additional factors such as equity or patient preferences for one procedure over another may need to also be taken into account . Results provide high-quality evidence to inform shared decision-making and treatment guidelines. Future work: Work is ongoing to disseminate findings and influence guidelines; patients have consented to longer-term follow-up. From an economics perspective, the currently available evidence shows that further research into patient preferences is important to inform the choice of surgical procedure. Trial registration: This trial is registered as ISRCTN 13930454. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 14/192/110) and is published in full in Health Technology Assessment ; Vol. 29, No. 55. See the NIHR Funding and Awards website for further award information.

21 March 2026 in Trials
Verified
Journal Article
Open access
PDF file
KTKatie Thomson
Katie Thomson
OAOpeyemi Agbeleye
Opeyemi Agbeleye
COChizoba Oparah
Chizoba Oparah
AIAlex Inskip
Alex Inskip
MBMatthew Breckons
Matthew Breckons
JWJames M. S. Wason
James M. S. Wason
Background: Adaptive designs (ADs) are increasingly used, whereby outcome data accumulated during the trial may inform a trial’s course in accordance with pre-specified rules at interim analyses. The benefits however will only be realised if the approaches to conducting interim analyses are optimised. This study aims to identify existing literature highlighting best practice (and existing evidence gaps) with regard to conducting high-quality, timely interim analyses. Methods: Medline and Embase databases were searched for studies published between 2005 and July 2025 to identify best practice models and lessons learned for interim analyses in the delivery of adaptive trials. Specifically, we considered papers that discussed adaptive trial methodological approaches (Phases II–IV) in any clinical population and condition. A narrative synthesis focused on the following outcomes was conducted: design considerations, project/trial management, data management, statistical processes, trial committee processes, the implementation of interim decisions and patient and public involvement and engagement (PPIE). Results: We screened 6720 articles from databases and citation chaining and assessed 329 articles at full text. One hundred and one articles representing 92 unique studies were deemed eligible for inclusion. Key issues included the following: (a) Detailed planning of interim analyses set out in the protocol, and all patient information sheets for possible changes prepared in advance; (b) Effective communication and collaborative decision-making processes across stakeholders, effective staff training, and prompt site query resolutions; (c) Use of electronic data capture with automated data flow processes with integrated query processes to improve data quality; and (d) Use of secure databases with data transfer procedures to maintain data integrity. Conclusion: The currently available data suggest that although there is a considerable volume of evidence with regards to the conduct of adaptive trials and good trial management, the existing literature base offers limited specific guidance for interim analyses. There are significant gaps in the literature regarding best practice guidance related to PPIE and statistical considerations in adaptive trials. While there are examples of innovative methods speeding up the collation and analysis of data used for interim analyses, we advocate more robust research exploring the operational opportunities and challenges with regards to undertaking adaptive trials.